Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says that it has drawn down on the £300,000 second deposit in respect of a previously announced equity prepayment facility.
In accordance with the terms of the facility, Sareum will issue 227,892 four year warrants over ordinary shares of 1.25p, each exercisable at a price of 82.93p to RiverFort Global Opportunities PLC.
Current stock price: 63.50 pence, up 1.6%
12-month change: down 23%
Copyright 2023 Alliance News Ltd. All Rights Reserved.